Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension
about
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideAdvanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug DeliveryNanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.Assessment of microRNA and gene dysregulation in pulmonary hypertension by endoarterial biopsy.Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formationUp-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertensionIn Vivo siRNA Delivery Using JC Virus-like Particles Decreases the Expression of RANKL in RatsDiscerning functional hierarchies of microRNAs in pulmonary hypertension.Nanotechnology: from In Vivo Imaging System to Controlled Drug Delivery.Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension.Nanocarriers as treatment modalities for hypertension.MicroRNA profiling identifies miR-129-5p as a regulator of EMT in tubular epithelial cells.The emerging role of microRNAs in hypoxia-induced pulmonary hypertension.New perspectives in nanotherapeutics for chronic respiratory diseases.Chimeric peptide-mediated siRNA transduction to inhibit HIV-1 infection.Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension.Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy.RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.Natural Antioxidants as Potential Therapy, and a Promising Role for Melatonin Against Pulmonary Hypertension.microRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.Silencing a Multifunctional microRNA Is Beneficial for Stroke Recovery.Non-Viral Based miR Delivery and Recent Developments.
P2860
Q26753129-E9618198-4030-458E-BCD6-620146B4D261Q28067306-E15341CD-AF8E-4612-84C8-80F3B062FC50Q28076132-42B07C72-8C6C-43BF-9160-F31CA0738411Q33737242-441A01CE-4B79-4730-A4D0-17E6CE3E8E32Q33788516-3971DB6F-F375-47F7-B01E-CC5F1E776511Q35995453-62615E2B-CCF7-4EF1-B55B-D8AF0A9F6D7DQ36996364-A5AB379A-1B44-4F04-AF18-5D928AE596D5Q37238758-B3A42BA4-3D1E-4768-BB27-CE8AB2739296Q37677437-5BFC511B-84BD-4B45-8F62-21967C155B2DQ38640456-1C65DC15-FDC7-4AF0-A118-131D94FB952AQ38682574-8645F737-6FF9-40AD-8521-3C3383CC4A43Q38757844-7D01A2C9-966D-498D-8C5E-D8169A1095F5Q38760963-243C5CE0-6DA9-4672-B1A7-4FB446ED225AQ38793540-1433F956-30E6-4274-A045-A1F4B3C98B09Q38827976-B0EF6EA5-A3A5-48E4-A76A-15996C180E7CQ40039105-E3ACD3AF-96BE-4FAC-9B70-870A77E6B1F5Q40472266-4C67EB40-8077-4080-9DA9-F5C96C8CDD5DQ41065352-378601D9-41A3-49CC-92E3-55962834D286Q41526246-5517CCBF-AF82-4789-B857-5FA3E381E35DQ42048496-696D39D1-5181-4129-914F-D96AD744DD85Q46183692-A9AAEDC0-60B6-4418-AAB6-16AB53DED0D0Q47302859-6CA8BEEE-8B62-4A89-897B-AC88E66D0776Q47699115-8CA43854-9876-4464-8B68-203B6FAE8BF3Q48298916-7ECF2D23-83D1-4A83-ABC2-D590577FF9BDQ49312062-8D00AD98-5FC2-4525-A19F-E2F4F281A1B1Q52661746-9FF27AEA-669A-4484-9354-002F3917300FQ54231141-912F02F3-CA27-4599-9B26-A3DF0C22EE9F
P2860
Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@ast
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@en
type
label
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@ast
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@en
prefLabel
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@ast
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@en
P2093
P2860
P1476
Lipid nanoparticle delivery of ...... imental pulmonary hypertension
@en
P2093
Ivan F McMurtry
Jason G Fewell
Jeff Sparks
Kohtaro Abe
Majed Matar
Masahiko Oka
Sachindra R Joshi
P2860
P356
10.1016/J.JCONREL.2015.05.261
P407
P577
2015-05-13T00:00:00Z